Advertisement

Infection

, Volume 46, Issue 3, pp 405–408 | Cite as

2016 PREP attitudes in Germany: high awareness and acceptance in MSM at risk of HIV

  • Christoph D. Spinner
  • Nikola Hanhoff
  • Ivanka Krznaric
  • Gaby Knecht
  • Tim Kuemmerle
  • Robin Ruesenberg
  • Knud Schewe
Brief Report

Abstract

Prupose

To examine current risk behavior, awareness, experience, and attitudes towards pre-exposure-prophylaxis (PrEP), and to estimate a potential impact on the prevention of HIV transmission among HIV-negative MSM in Germany. PrEP was not officially licensed at the time of survey.

Methods

Web-based questionnaire from 03–06/2016. Potential participants were informed through social media, flyers, and advertisements. Risk contacts were defined as unprotected sexual intercourse under the influence of recreational drugs in the past 6 months.

Results

In total, 1208 subjects participated, 342 subjects were excluded for being HIV-infected or non-MSM, leaving 866 subjects to be evaluated in this analysis. Mean age was 37.0 ± 10.4 years. 593 participants (68.5%) were tested for HIV within the past 12 months. A total of 206 STDs in the past 6 months were reported by 144 (16.6%). Aware of PrEP was 748 (86.4%) respondents, while 65.1% reported willingness to use it. Risk behavior was significantly associated with higher PrEP acceptance (OR 2.90, 95% CI 2.14–3.90), as was a history of STDs (OR 1.85, 95% CI 1.17–2.91). The use of condoms would forgo 52.3% of subjects if taking PrEP. Sixty-five respondents (7.5%) reported PrEP use. Only 19 (29.2%) had accessed PrEP under medical supervision. PrEP use was reported by 14.8% with > 5 risk contacts in the past 6 months, compared to 6.3% with one risk contact (p < 0.001).

Conclusion

We found a high PrEP awareness and acceptance, especially among subgroups of MSM at highest risk of HIV infection. Structured access and availability of PrEP to this population may have an important impact on the HIV epidemic in Germany.

Keywords

HIV PrEP Prevention MSM 

Notes

Funding

No additional funding has been provided for this study.

Compliance with ethical standards

Conflict of interest

All authors declare that there is no relevant conflict of interest.

References

  1. 1.
    Spinner CD, Boesecke C, Zink A, Jessen H, Stellbrink H-J, Rockstroh JK, et al. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016;44:151–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237–46.CrossRefPubMedGoogle Scholar
  3. 3.
    McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet Lond Engl. 2016;387:53–60.CrossRefGoogle Scholar
  4. 4.
    RKI, Archiv (2016) Epidemiologisches bulletin 38/2016 (Internet). (cited 2018 Jan 31). Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2016/Ausgaben/38_16.pdf. Accessed 31 Jan 2018.
  5. 5.
    2016_05_11_schwule_maenner_und_hiv_aids_2013.pdf (Internet). (cited 2018 Jan 31). Available from: https://www.aidshilfe.de/shop/pdf/7850. Accessed 31 Jan 2018.
  6. 6.
    European Centre for Disease Prevention and Control. Evidence brief: pre-exposure prophylaxis for HIV prevention in Europe. Stockholm: ECDC; 2016. p. 1–8.Google Scholar
  7. 7.
    Knecht G, Hanhoff N, Bodtländer A, Ingiliz P, Krznaric I. Attitudes towards pre-exposure prophylaxis (PrEP) among MSM in Germany [abstract MOPE132]. Kuala Lumpur, Malaysia: 7th IAS Conference 2013.Google Scholar
  8. 8.
    Molina J-M, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4:e402–10.CrossRefPubMedGoogle Scholar
  9. 9.
    Russel D. Epidemiology of STIs in the HIV and AIDS era. 9th IAS Conference Paris 2017.Google Scholar
  10. 10.
    Jenness SM, Weiss KM, Goodreau SM, Gift T, Chesson H, Hoover KW, et al. Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017;65:712–8.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Christoph D. Spinner
    • 1
  • Nikola Hanhoff
    • 2
  • Ivanka Krznaric
    • 3
  • Gaby Knecht
    • 4
  • Tim Kuemmerle
    • 5
  • Robin Ruesenberg
    • 2
  • Knud Schewe
    • 2
    • 6
  1. 1.Department of Medicine IIUniversity Hospital Klinikum Rechts der Isar, Technische Universität MünchenMunichGermany
  2. 2.German Association of Physicians Specialized in HIV Care (Dagnä e.V.)BerlinGermany
  3. 3.Zentrum für Infektiologie Prenzlauer BergBerlinGermany
  4. 4.InfektiologikumFrankfurtGermany
  5. 5.Praxis am EbertplatzCologneGermany
  6. 6.Infektionsmedizinisches Centrum Hamburg, Private PracticeHamburgGermany

Personalised recommendations